Edition:
United Kingdom

Biocept Inc (BIOC.OQ)

BIOC.OQ on NASDAQ Stock Exchange Capital Market

1.02USD
9:00pm BST
Change (% chg)

$0.01 (+0.99%)
Prev Close
$1.01
Open
$1.01
Day's High
$1.03
Day's Low
$1.01
Volume
25,315
Avg. Vol
545,813
52-wk High
$12.12
52-wk Low
$0.66

Latest Key Developments (Source: Significant Developments)

Biocept Q3 Loss Per Share $2.42
Tuesday, 13 Nov 2018 

Biocept Inc ::BIOCEPT REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $2.42.Q3 REVENUE $762,000 VERSUS I/B/E/S VIEW $948,000.Q3 EARNINGS PER SHARE VIEW $-2.02 -- THOMSON REUTERS I/B/E/S.CASH AND CASH EQUIVALENTS AS OF SEPTEMBER 30, 2018 WERE $9.0 MILLION, COMPARED WITH $2.1 MILLION AS OF DECEMBER 31, 2017.  Full Article

Biocept Announces Pricing Of $2.5 Mln Registered Direct Offering
Friday, 21 Sep 2018 

Sept 21 (Reuters) - Biocept Inc ::BIOCEPT ANNOUNCES PRICING OF $2.5 MILLION REGISTERED DIRECT OFFERING PRICED AT MARKET.BIOCEPT INC - COMBINED PURCHASE PRICE FOR ONE SHARE OF COMMON STOCK AND EACH WARRANT WILL BE PRICED AT $3.285.  Full Article

Biocept Q1 Loss Per Share $0.11
Tuesday, 15 May 2018 

May 15 (Reuters) - Biocept Inc ::BIOCEPT REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.11.Q1 REVENUE $800,000 VERSUS $1.7 MILLION.  Full Article

Biocept Reports Q4 Loss Of $0.18 Per Share
Wednesday, 28 Mar 2018 

March 28 (Reuters) - Biocept Inc ::BIOCEPT REPORTS 2017 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.18.‍REVENUES FOR Q4 2017 WERE $1.0 MILLION, COMPARED WITH $1.3 MILLION FOR Q4 OF 2016​.‍CASH AND CASH EQUIVALENTS WERE $2.1 MILLION AS OF DEC 31, 2017, COMPARED WITH $4.6 MILLION LAST YEAR.  Full Article

Biocept And Thermo Fisher Scientific Enter Into Technology And Commercial Collaboration
Wednesday, 28 Mar 2018 

March 28 (Reuters) - Biocept Inc ::BIOCEPT AND THERMO FISHER SCIENTIFIC ENTER INTO TECHNOLOGY AND COMMERCIAL COLLABORATION.BIOCEPT INC - ENTERED INTO A NON-BINDING MEMORANDUM OF UNDERSTANDING WITH THERMO FISHER SCIENTIFIC, INC. TO COLLABORATE TOGETHER COMMERCIALLY​.BIOCEPT - P‍LAN TO VALIDATE THERMO FISHER'S ONCOMINE NEXT-GENERATION SEQUENCING LIQUID BIOPSY PANELS IN BIOCEPT'S CLIA-CERTIFIED LABORATORY​.  Full Article

Biocept Inc Says Signed An In-Network Provider Agreement With Wellmark Inc
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Biocept Inc ::BIOCEPT INC - HAS SIGNED AN IN-NETWORK PROVIDER AGREEMENT WITH WELLMARK INC.  Full Article

Sabby Management LLC Reports A 9.20 Pct Passive Stake In Biocept
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - Biocept Inc ::SABBY MANAGEMENT LLC REPORTS A 9.20 PCT PASSIVE STAKE IN BIOCEPT INC <<>> AS OF DEC 5 - SEC FILING.  Full Article

Biocept announces pricing of public offering of up to 4,925,936 shares of common stock
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - Biocept Inc ::BIOCEPT ANNOUNCES PRICING OF PUBLIC OFFERING OF UP TO 4,925,936 SHARES OF COMMON STOCK.BIOCEPT - ‍PRICED BEST EFFORTS REGISTERED PUBLIC OFFERING OF UP TO 4.9 MILLION SHARES OF CO'S COMMON STOCK AT PRICE TO PUBLIC OF $0.68/SHARE​.  Full Article

Biocept files for offering $10 mln of shares of co's common stock and warrants
Friday, 17 Nov 2017 

Nov 17 (Reuters) - Biocept Inc :Biocept Inc files for offering $10 million of shares of co's common stock and warrants - SEC Filing.Biocept - shares of co's common stock and warrants are immediately separable and will be issued separately, but will be purchased together in the offering.  Full Article

Biocept reports Q3 loss per share $0.20
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Biocept Inc :Biocept reports third quarter 2017 financial results.Q3 loss per share $0.20.Q3 revenue rose 6 percent to $1.1 million.Biocept Inc - ‍cash and cash equivalents were $5.9 million as of September 30, 2017​.  Full Article

BRIEF-Biocept And Prognos Enter Into Partnership

* BIOCEPT AND PROGNOS ENTER INTO PARTNERSHIP TO APPLY ARTIFICIAL INTELLIGENCE IN ORDER TO HELP PHARMACEUTICAL AND LIFE SCIENCES COMPANIES OPTIMIZE COMMERCIALIZATION OF BIOMARKER-TARGETED THERAPIES IN ONCOLOGY Source text for Eikon: Further company coverage: